In fact, elevated NQO1 expression (≥tenfold) has been observed in ~90 % of PDA patient specimens, making PDA an especially appealing target for therapy using NQO1-bioactivatable drugs, such as ß-lap [18–21]. The gene discussed is NQO1; the disease is Patent ductus arteriosus.